Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986762 | 0.82 | DGAT1 (0.50) | DGAT1USP2SMN1; SMN2ELANETDP1 | |
| SCHEMBL28514623 | 0.78 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL307610 | 0.75 | DGAT1 (0.55) | DGAT1USP2SMN1; SMN2ELANETDP1 | |
| SCHEMBL3141601 | 0.75 | DGAT1 (0.79) | DGAT1USP2SMN1; SMN2ELANETDP1 | |
| Hydrogen Peroxide SCHEMBL25411902 | 0.73 | DGAT1 (0.52) | DGAT1USP2SMN1; SMN2ELANEALDH1A1 | |
| SCHEMBL20565054 | 0.73 | DGAT1 (0.52) | DGAT1USP2SMN1; SMN2ELANETDP1 | |
| SCHEMBL8207418 | 0.73 | DGAT1 (0.52) | DGAT1USP2SMN1; SMN2ELANETDP1 | |
| SCHEMBL362903 | 0.73 | DGAT1 (0.52) | DGAT1USP2SMN1; SMN2ELANETDP1 | |
| SCHEMBL4677923 | 0.73 | DGAT1 (0.52) | DGAT1USP2SMN1; SMN2ELANETDP1 | |
| SCHEMBL1316670 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994049-B | Synthesis method of ceftazidime side chain ethyl ester | 山东金城医药化工有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-118994049-A | Synthesis method of ceftazidime side chain ethyl ester | 山东金城医药化工有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230357166-A1 | PIPERAZINE-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-3018118-B1 | BASE GENERATOR, BASE-REACTIVE COMPOSITION CONTAINING SAID BASE GENERATOR, AND BASE GENERATION METHOD | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-10428014-B2 | Base generator, base-reactive composition containing said base generator, and base generation method | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20170143841-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143841-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170007710-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3018118-A1 | BASE GENERATOR, BASE-REACTIVE COMPOSITION CONTAINING SAID BASE GENERATOR, AND BASE GENERATION METHOD | Wako Pure Chemical Industries, Ltd. (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20160122292-A1 | BASE GENERATOR, BASE-REACTIVE COMPOSITION CONTAINING SAID BASE GENERATOR, AND BASE GENERATION METHOD | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2016-05-05 | — | — | US | disclosed |
| CN-105339340-A | Base generator, base-reactive composition containing said base generator, and base generation method | WAKO PURE CHEM IND LTD | 2016-02-17 | — | — | CN | disclosed |
| US-20150004128-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS, LLC (US) | 2015-01-01 | — | — | US | disclosed |
| US-8765432-B2 | Targeted drug phosphorylcholine polymer conjugates | OLIGASIS, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140024776-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130034517-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-07 | — | — | US | disclosed |
| US-7528276-B2 | Process for preparing the intermediate compounds for PPAR α ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-05-05 | — | — | US | disclosed |
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-10-30 | — | — | US | disclosed |
| EP-1975712-A2 | Positive resist composition and pattern forming method using the same | FUJIFILM Corporation (JP) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428014-B2 | Base generator, base-reactive composition containing said base generator, and base generation method | HPRT1, GNG2, BLM | DGAT1 2256/4885USP2 4835/4885SMN1; SMN2 4004/4885 |
| US-20230357166-A1 | PIPERAZINE-BASED CATIONIC LIPIDS | NPC1L1, SREBF2, NPC1 | DGAT1 1177/4885USP2 3770/4885SMN1; SMN2 1012/4885 |
| US-20130034517-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | PHOSPHO1, EPHA2, PCTP | DGAT1 1552/4885USP2 2122/4885SMN1; SMN2 1685/4885 |
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | PPARG, PPARA, PPARD | DGAT1 255/4885USP2 2404/4885SMN1; SMN2 4766/4885 |
| US-20170143841-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | ACP1, PHOSPHO1, PARG | DGAT1 1505/4885USP2 2285/4885SMN1; SMN2 3214/4885 |
| US-20170007710-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | PHOSPHO1, EPHA2, PCTP | DGAT1 1552/4885USP2 2122/4885SMN1; SMN2 1685/4885 |
| US-20140024776-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | ACP1, PHOSPHO1, PARG | DGAT1 1505/4885USP2 2285/4885SMN1; SMN2 3214/4885 |
| US-20150004128-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | PHOSPHO1, EPHA2, PCTP | DGAT1 1552/4885USP2 2122/4885SMN1; SMN2 1685/4885 |
| US-20160122292-A1 | BASE GENERATOR, BASE-REACTIVE COMPOSITION CONTAINING SAID BASE GENERATOR, AND BASE GENERATION METHOD | GNG2, EPHX2, ARHGEF1 | DGAT1 1616/4885USP2 4724/4885SMN1; SMN2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.